Loading clinical trials...
Loading clinical trials...
This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more
NCT07042100 · Advanced Solid Tumors
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT07087197 · Metastatic Solid Tumors
Premiere Oncology
Santa Monica, California
Indiana University Med Center
Indianapolis, Indiana
University Of Wisconsin Comprehensive Center
Madison, Wisconsin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions